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Background: Efficacy of cancer vaccines may be limited due to immune escape mechanisms like loss or mutation
of target antigens. Here, we analyzed 10 HLA-A2 positive patients with acute myeloid leukemia (AML) for loss or
mutations of the WT1 epitope or epitope flanking sequences that may abolish proper T cell recognition or epitope
presentation.
Methods: All patients had been enrolled in a WT1 peptide phase II vaccination trial (NCT00153582) and ultimately
progressed despite induction of a WT1 specific T cell response. Blood and bone marrow samples prior to
vaccination and during progression were analyzed for mRNA expression level of WT1. Base exchanges within the
epitope sequence or flanking regions (10 amino acids N- and C-terminal of the epitope) were assessed with
melting point analysis and sequencing. HLA class I expression and WT1 protein expression was analyzed by flow
cytometry.
Results: Only in one patient, downregulation of WT1 mRNA by 1 log and loss of WT1 detection on protein level at
time of disease progression was observed. No mutation leading to a base exchange within the epitope sequence
or epitope flanking sequences could be detected in any patient. Further, no loss of HLA class I expression on
leukemic blasts was observed.
Conclusion: Defects in antigen presentation caused by loss or mutation of WT1 or downregulation of HLA
molecules are not the major basis for escape from the immune response induced by WT1 peptide vaccination.
Background
Over-expression of Wilms’ tumor gene 1 (WT1) is present
in a variety of malignant tumors, including acute leuke-
mias [1-3] and a variety of solid neoplasms [4]. The WT1
protein is a transcription factor critically involved in
tumor cell proliferation, making it a suitable target for
therapeutic strategies including vaccine approaches [5].
Clinical vaccination trials with WT1 peptides and protein
in AML/MDS have been recently initiated leading to the
induction of epitope specific cytotoxic T cells and unpre-
cedented clinical efficacy [6-8]. However, even in case of
induction of a robust T cell response cancer vaccines in
general have only limited efficacy. Several immune escape
mechanisms have been identified [9-11]. Important escape
mechanisms on tumor cell site are loss or downregulation
of tumor associated antigens (TAA) and mutation of TAA
[12,13]. A mutation within the sequence of an epitope
may abolish proper HLA class I binding, T cell recognition
or proteasomal processing. Another less recognised
mechanism interfering with antigen presentation may be a
mutation of the flanking sequence of an epitope that may
prohibit or decrease processing of the epitope by the pro-
teasome or extraproteasomal proteases [14,15]. In addi-
tion, antigen presentation can be distorted by mechanisms
such as decrease in HLA class I expression [16-18] or
alterations in the antigen processing pathway [19-21]. * Correspondence: antonia.busse@charite.de
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Patients were treated within a phase II vaccination trial
(NCT00153582) [8] and received sequential vaccinations
with the HLA-A2-restricted WT1 126-134 peptide +
KLH and GM-CSF as adjuvants. Detailed patient charac-
teristics are previously published in Keilholz et al 2009:
p a t i e n tn o1 ;n o4 ;n o5 ;n o8 ;n o9 ;n o1 1 ;n o1 2 ;n o
13; no 15; one patient is not published yet) [8]. All
patients gave written informed consent to participate in
the study according to the Declaration of Helsinki. The
study was approved by the local ethics board.
Blood and bone marrow samples
Bone marrow and peripheral blood samples have been
collected before vaccination and during progression in
heparinized tubes and mononuclear cells (MNCs) were
isolated by Ficoll Isopaque density gradient centrifuga-
tion (Pharmacia, Germany).
mRNA extraction and reverse transcription
Samples were resuspended in guanidium thiocyanate
(GTC) buffer and stored at -80°C. Further processing of
samples was performed as previously described [22]. In
brief, total RNA was isolated by RNeasy Mini Kit
including RNase-Free DNase Set (Qiagen, Germany)
according to the manufactures recommendations. For
reverse transcription, Omniscript Reverese Transcriptase
kit (Qiagen, Germany) was used.
Quantification of WT1 expression levels
Quantitative Real Time RT-PCR assays were performed
using a LightCycler (Roche Diagnostics) with specific
primers for WT1 and the housekeeping gene porpho-
bilinogen deaminase (PBGD) as described elsewhere
[22]. For quantification, PCR products generated from
WT1 cDNAs and from porphobilinogen deaminase
(PBGD) cDNAs were cloned into the vector pCR2.1-
TOPO (Invitrogen, The Netherlands). A standard
curve with 3 dilutions of the appropriate plasmid in
duplicates was included in each PCR run. Analysis of
RT-PCR expression data was performed with the
LightCycler software (version 3). Crossing points were
assessed by the second derivate maximum algorithm
and plotted against the concentrations of the stan-
dards. Sample concentrations were calculated using the
plasmid standard curve resulting in marker concentra-
tions. All samples were analysed in duplicate. The
average value of both duplicates was used as a quanti-
tative value. To correct for differences of cDNA
amount on a per-sample basis, results were provided
a sr a t i ot oP B G De x p r e s s i o n .
Mutation analysis
Base exchanges within the epitope sequence or epitope
flanking sequences (10 amino acids N- and C-terminal
of the epitope) were analyzed with melting point analy-
sis after amplification with the specific primers WT1
Mut fw 5’-TGTCCACTTTTCCGGC-3’ and WT1 Mut
rev 5’-GTCCCGTCGAAGGTGA-3 on a LightCycler
instrument. To cover the whole sequence 2 wild-type
complementary detection probe pairs were used (P,
dephosphorylated; X, Fluorescein; Y, LC Red 640): probe
pair 1: 5’-Y GCGCGTTAGGAAACATCCTGG P, 5’-
TGGCCGGATGACGCCTGG X, probe pair 2: 5’-Y
CTGGGCAGGTAGGGC P, 5’-TTAGGAAACATCCTG
GCCTGGCCG X. To confirm the results obtained by
melting curve analysis sequencing was performed in 4
patients.
Flow cytometry
For determination of HLA Class I expression and HLA-
A2 expression, leukemic blasts were stained with FITC
conjugated anti-HLA class I monoclonal antibody
(mAb) B9.12.1 (Beckmann Coulter) and with Alexa 647
conjugated mAb anti-HLA-A2 BB7.2 (AbSerotec)
respectively. For exclusion of monocytes and lympho-
cytes samples were additionally stained with PerCP con-
jugated anti CD3 mAb and anti CD14 mAb (both BD
Bioscience) and for exclusion of dead cells the LIVE/
DEAD Fixable Violet Dead Cell Stain Kit (Molecular
Probes) was used. For detection of WT1 expression in
leukemic blasts extracellular staining was done with PE-
conjugated mAb against CD34 (Becton Dickinson) and
intracellular staining with mAbs against WT1 (clone 6F-
H2, Dako) as primary antibody and goat anti mouse
(GAM)-FITC (JacksonImmunoResearch) as secondary
antibody. T cell response assessment was carried out as
described in detail in Keilholz et al 2009 [8]. A cytokine
response was considered positive if the percentage of
WT1-peptide-specific cytokine producing CD3+CD8+T
cells was at least 2-fold the percentage of cytokine pro-
ducing CD3+CD8+T cells in response to an HIV control
peptide; a tetramer response was considered positive if
the frequency of tetramer positive CD3+CD8+ T cells
exceeded 0.3%, which was the mean + 2 standard devia-
tions (0.16% + 0.14%) observed in 12 healthy control
subjects.
Data acquisition was performed on a FACSCalibur
(Becton Dickinson) and data were analyzed using Cell-
Quest software.
Results and Discussion
Ten HLA-A2 positive patients with AML were analysed
for mRNA expression levels of WT1 and for mutations
of the WT1 epitope or epitope flanking sequences. All
patients had received sequential vaccinations with the
HLA-A2-restricted WT1 126-134 peptide with adjuvants
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an initial interval of vaccine efficacy [8]. T cell response
to vaccination was analyzed as previously published in
Keilholz et al 2009 (patient no 1; no 4; no 5; no 8; no 9;
no 11; no 12; no 13; no 15; one patient is not published
yet) [8]: In 8 of these 10 patients WT1 126-134 tetramer
+ T cells during the course of vaccination were found in
peripheral blood (mean percentage of WT1 126-134 tet-
ramer + cells in the CD3+ CD8+ T cell population
0.76% [0.3%-1.09%]). Moreover, to analyze the functional
activity of WT1 126-134 specific T cells raised by vacci-
nation, the reactivity of CD3+CD8+ T cells against
WT1 126-134 peptide loaded cells was measured by
intracellular IFN-g and/or TNF-a cytokine staining. In 8
of 10 patients the presence of TNF-a and/or IFN-g pro-
ducing WT1 126-134 specific CD3+CD8+ T cells could
be induced by vaccination. 7 patients showed a TNF-a
response with a mean percentage of TNF-a+ cells in
the CD3+CD8+ T cell population of 0.26% (0.1% - 0.6%)
and 7 patients showed a IFN-g response with a mean
percentage of IFN-g+ cells in the CD3+CD8+ T cell
population of 0.23% (0.09-0.6%). However, one patient
showed no WT1 126-134 tetramer + T cells or cytokine
response in peripheral blood.
As loss or downregulation of tumor antigens are poten-
tial immune escape mechanisms [12,13], first bone mar-
row samples obtained before vaccination and during
progression were analyzed for expression levels of WT1
by real-time RT-PCR. In 9 out of 10 patients bone mar-
row WT1 levels were constant or increased at the time
point of progression mirroring the kinetics of bone mar-
row blasts during treatment (figure 1). In one patient,
however, down-regulation of WT1 by 1 log was observed
although bone marrow blasts reached the same level at
time of disease progression as before vaccination. In this
latter patient WT1 protein was undetectable by intracel-
lular flow cytometry at time of disease progression, con-
sistent with downregulation of WT1 mRNA and protein
as escape mechanism in this single patient.
WT1 mutations have been reported in about 10% of
patients with AML [23]. They were frequently observed
in DNA binding portions of the WT1 protein and may
therefore contribute to leukemogenesis [24]. However,
mutations have also been observed in exon 1, affecting
the epitope flanking regions of the WT1 126-134 epi-
tope [23]. Mutations of the epitope sequence or its
flanking sequences could represent a possible immune
escape mechanism as they may abolish proper HLA
class I binding, T cell recognition or proteasomal pro-
cessing. Therefore, mutation analysis was performed in
both samples obtained before vaccination and during
progression. However, no mutation leading to a base
exchange within the epitope sequence or epitope flank-
ing sequences could be detected in any patient. As
expected, the known single nucleotide polymorphism C/
T (NM_000378, mRNA position 790, coding position 3,
protein residue Asn) at amino acid position 130 was
observed in 6 patients.
To exclude failure of vaccine efficacy due to HLA
class I downregulation [16-18,25], cell surface HLA class
I expression on leukemic blasts was analyzed in 9
patients by flow cytometry during progression. The
median percentage of HLA class I expressing blasts was
96% (84%-99%). Compared to HLA class I expression
on blasts before therapy (5 patients analyzed) there was
no significant downregulation. To exclude selective loss
of the HLA-A2 allele, we analyzed HLA-A2 expression
on leukemic blasts of 5 patients. In all 5 patients more
than 90% of blasts stained positive for HLA-A2. In none
of the patients a difference of HLA-A2 expression before
therapy and at the time point of progression was
observed.
Conclusions
We have no evidence for an immune escape due to loss
or mutation of WT1 or HLA class I downregulation as
has been reported for immunotherapy targeting differen-
tiation antigens in melanoma [12]. This finding supports
the use of tumor target antigens like WT1 which are
crucial for tumor cell proliferation. However, further
studies, especially on mechanisms of immune evasion at
the effector phase of the anti-tumor immune response,
are indicated to determine potential inhibitory immune
mechanisms during WT1 peptide vaccination.
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